Gilead Sciences Announces First Quarter 2024 Financial Results
Gilead Sciences, Inc. (GILD)
Last gilead sciences, inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.gilead.com
Company Research
Source: Business Wire
Product Sales Excluding Veklury Increased 6% Year-Over-Year to $6.1 billionBiktarvy Sales Increased 10% Year-Over-Year to $2.9 billionOncology Sales Increased 18% Year-Over-Year to $789 millionClosed CymaBay Acquisition Resulting in $3.9 billion Acquired IPR&D Charge ($3.14 Diluted EPS Impact) FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its first quarter 2024 results of operations.“Gilead delivered another strong quarter of revenue growth in the first quarter with 6% year-over-year growth in our base business driven by HIV, Oncology and Liver Disease,” said Daniel O’Day, Gilead’s Chairman and Chief Executive Officer. “The acquisition of CymaBay brings us another potentially transformative therapy for people with liver disease, and a regulatory decision on seladelpar is expected in August. New HIV data demonstrates the continued progress in our long-acting HIV pipeline, and we look forward to providing updates on this and our broad Onco
Show less
Read more
Impact Snapshot
Event Time:
GILD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GILD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GILD alerts
High impacting Gilead Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
GILD
News
- Forbes Has Listed Gilead as One of America's Best Employers for Diversity [Yahoo! Finance]Yahoo! Finance
- Gilead Sciences, Inc. (NASDAQ: GILD) had its price target lowered by analysts at Maxim Group from $90.00 to $85.00. They now have a "buy" rating on the stock.MarketBeat
- Gilead Sciences to Present at Upcoming Investor ConferencesBusiness Wire
- Gilead Sciences, Inc. (NASDAQ:GILD) Q1 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Gilead Sciences, Inc. (NASDAQ: GILD) had its price target lowered by analysts at Barclays PLC from $80.00 to $76.00. They now have an "equal weight" rating on the stock.MarketBeat
GILD
Earnings
- 4/25/24 - Beat
GILD
Sec Filings
- 4/26/24 - Form 4
- 4/25/24 - Form 8-K
- 4/2/24 - Form 4
- GILD's page on the SEC website